Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $480000.0.

  • Viking Therapeutics' Cash from Financing Activities fell 8096.75% to $480000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 9961.81%. This contributed to the annual value of $612.5 million for FY2024, which is 12568.83% up from last year.
  • Latest data reveals that Viking Therapeutics reported Cash from Financing Activities of $480000.0 as of Q3 2025, which was down 8096.75% from $507000.0 recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Cash from Financing Activities registered a high of $606.0 million during Q1 2024, and its lowest value of -$5.0 million during Q1 2022.
  • Its 5-year average for Cash from Financing Activities is $47.2 million, with a median of $507000.0 in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 2277021.28% in 2022, then plummeted by 84000.0% in 2023.
  • Over the past 5 years, Viking Therapeutics' Cash from Financing Activities (Quarter) stood at $47000.0 in 2021, then soared by 22770.21% to $10.7 million in 2022, then plummeted by 98.25% to $188000.0 in 2023, then surged by 431.91% to $1.0 million in 2024, then crashed by 52.0% to $480000.0 in 2025.
  • Its last three reported values are $480000.0 in Q3 2025, $507000.0 for Q2 2025, and $349000.0 during Q1 2025.